The PM Society Market Access Interest Group (MAIG) is gearing up to host its next in-person meeting on Tuesday, May 23rd, at the prestigious Royal Society of Medicine in London.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh